Proton pump inhibitors (PPIs) are a class of medications that reduce stomach acid production. They are often used to treat heartburn, indigestion, and acid reflux.
This study aimed to examine whether concomitant PPI use is associated with survival in patients with metastatic prostate cancer treated with androgen deprivation therapy (ADT) and AAP.
“Post-hoc analysis was conducted in patients with metastatic castration-sensitive prostate cancer (mCSPC) and metastatic castration-resistant prostate cancer (mCRPC) treated in the LATITUDE, COU-AA-301, and COU-AA-302 trials (ADT vs. ADT plus AAP).”
The study indicated: “PPI use may be associated with inferior survival in patients with metastatic prostate cancer who receive ADT plus AAP. Discontinuing unnecessary PPI use might improve those outcomes.”
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials
Wataru Fukuokaya, Keiichiro Mori, Takafumi Yanagisawa, Kohei Akazawa, Tatsuya Shimomura & Takahiro Kimura
Prostate Cancer and Prostatic Diseases volume 27, pages 444–450 (2024)
DOI